This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Aubagio — Description, Dosage, Side Effects | PillsCard
Rx
Aubagio
14 mg, Tabletki powlekane
INN: Teriflunomidum
Data updated: 2026-04-13
Available in:
🇩🇪🇬🇧🇵🇱🇹🇷
Form
Tabletki powlekane
Dosage
14 mg
Route
doustna
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Sanofi Winthrop Industrie (Francja)
Composition
Teriflunomidum 14 mg
ATC Code
L04AA31
Source
URPL
Aubagio is the originator brand of teriflunomide 14 mg, an oral once-daily disease-modifying therapy for relapsing forms of multiple sclerosis manufactured by Sanofi/Genzyme. Teriflunomide is the active metabolite of leflunomide and a selective, reversible inhibitor of dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme essential for the de novo synthesis of pyrimidines. By depleting pyrimidine pools in rapidly dividing activated T- and B-lymphocytes, teriflunomide reduces autoreactive lymphocyte proliferation and CNS infiltration while sparing resting and memory lymphocytes that can use the salvage pathway. ATC class L04AA31. Steady-state plasma concentrations are reached after several months because of the long elimination half-life (approximately 19 days) and extensive enterohepatic recirculation.
⚠️ Warnings
Liver function: measure ALT before initiation and monthly for the first 6 months, then every 8 weeks; discontinue if ALT > 3x ULN persistently or > 5x ULN. Pregnancy: women must use effective contraception during therapy and undergo accelerated elimination procedure (cholestyramine 8 g three times daily for 11 days, or activated charcoal 50 g twice daily for 11 days) if pregnancy is planned or occurs — plasma teriflunomide must fall below 0.02 mg/L confirmed on two tests at least 14 days apart. Men planning fatherhood: similar accelerated elimination is recommended. Monitor blood pressure at baseline and periodically. Full blood count and TB screening before initiation. Live vaccines should be avoided during therapy and for up to 2 years after stopping (until plasma drug levels are confirmed low). Driving: caution with neurological adverse effects.
